While the use of glucagon-like peptide-1 (GLP-1) analogs in the control of diabetes has been associated with appetite suppression and reduced food intake, substantial numbers of patients exhibit gastrointestinal side effects (nausea, emesis) and average weight loss has ranged from 1 to 7% in studies leading to approval6. This evidence concerns the gene GCG and diabetes mellitus.